This activity was originally broadcast live as a satellite symposium held in conjunction with AMCP Disparities Summit
Program Description
Endometrial cancer is the most common gynecologic malignancy in the United States. Primary prevention, early detection, and treatment have a large impact on patient outcomes. Unfortunately, disparities including biologic/genetic, behavioral, and social determinants affect patient access to care. This activity will highlight the role of managed care professionals in caring for patients with endometrial cancer, specifically focusing on potential disparities in care. Additionally, the use of biomarkers to guide therapy selection will also be reviewed, with an emphasis on guideline-recommended treatment strategies.
Target audience: Health System Pharmacist, Managed Care Pharmacist, Oncology Pharmacist
Type of activity: Application
Release date: August 18, 2022
Expiration date: March 1, 2024
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the prognosis of metastatic endometrial cancer and the significance of biomarkers in determining appropriate therapy.
- Investigate health equity issues affecting patients with endometrial cancer and the potential impact of disparities on clinical outcomes.
- Interpret evidence-based guidelines and clinical trial data in the use of targeted therapies for the treatment of endometrial cancer.
- Identify best practices for implementing evidence-based treatment to maximize cost-effectiveness of immunotherapies and mitigate the disparities in health equity for patients with endometrial cancer.
Onye J. Ononogbu PharmD, BCOP
Research Assistant Professor
Department of Pharmacy Practice and Translational Research
University of Houston College of Pharmacy
Hematology/Oncology Clinical Pharmacy Specialist
Harris Health System
Co-founder & Chief Program Officer
Pharmacy Initiative Leaders, Inc. (PILs)
Laura R. Bobolts, PharmD, BCOP
Senior Vice President
Clinical Strategy and Growth
OncoHealth
Plantation, Florida
Kellie Jones Weddle, PharmD, BCOP, FCCP, FHOPA
Clinical Professor
Purdue University College of Pharmacy
Department of Pharmacy Practice
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-289-H01-P. The activity is available for CE credit through August 18, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Kellie Jones Weddle, PharmD, BCOP, FCCP, FHOPA, has the following financial relationship with a commercial interest to disclose:
Speaker's Bureau: Janssen Educational Program
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Onye J. Ononogbu PharmD, BCOP
Laura R. Bobolts, PharmD, BCOP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Meg Taylor, PharmD, CPP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.
Pharmacy Times® Editorial Staff—Davy James
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here